Effects of memantine and clopidogrel alone and in combination in a cerebral ischemia-reperfusion model

Özdemir, Haşan; İlhan, Selçuk; Demir, Caner Feyzi; Akgun, Bekir; Kapan, Oktay; Ataş, Eser; Berilgen, M. Said; Balduz, Metin

doi:10.1016/j.npbr.2014.08.003

Cited by 2 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it can prevent calcium homeostasis disorder and increase free radicals [21]. Further, in the study of Özdemir, it was found that Memantine can reduce the oxidative stress in ischemic brain injuries [22].…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Effect of Memantine on Oxidative and Antioxidant Indexes Among Elderly Patients with Prediabetes and Mild Cognitive Impairment

Alimoradzadeh¹,

Mirmiranpour²,

Hashemi³

et al. 2019

J Neurol Neurophysiol

View full text Add to dashboard Cite

Objective: Mild cognitive impairment (MCI) is a cognitive syndrome in the elderly individuals. MCI drug treatment is still under debate. On the other hand, MCI progress is higher in people with diabetes mellitus type 2. This study was designed to determine the effect of Memantine on oxidant and antioxidant indexes among the elderly with prediabetes and MCI. Method: The present study is a double-blind randomized clinical trial which was conducted on 50 elderly patients over 60 years of age who had been diagnosed with prediabetes and MCI. Subjects were divided into intervention and control groups. The intervention group was treated with Memantine and Metformin and the control group received Metformin only. The data were collected before and after the study by blood tests and clinical examination and analyzed by using correlation test, independent and paired sample t-test in SPSS v.23 software. Results: The subjects included 22 men and 28 women. The mean age subject was 72.87 ± 3.95. Regarding the control group, the oxidative indexes including Advanced Glycation End Products (AGEs) and Advanced oxidation protein products (AOPP) decreased significantly (p value<0.001, df: 48). Regarding the intervention group, the oxidant indexes including AGEs and AOPP significantly decreased. In addition, antioxidant indexes such as LAP and Lecithin-cholesterol acyltransferase (LCAT) indexes increased considerably (p value<0.001, df: 48). Conclusion: Based on the results, the combination therapy with Memantine and Metformin for elderly patients with Prediabetic State and MCI may decrease oxidant indexes and increase the effect on antioxidant indices.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Memantine is a non-competitive inhibitor for N-methyl-D-aspartate receptor, which prevents over-stimulation of this NMDA-receptor by Glutamate (a defective memory factor in Alzheimer's disease) [20]. A large body of research suggested that Memantine can reduce the production of free radicals [21,22].…”

Section: Introductionmentioning

confidence: 99%

Effect of Memantine on Oxidative and Antioxidant Indexes Among Elderly Patients with Prediabetes and Mild Cognitive Impairment

Alimoradzadeh¹,

Mirmiranpour²,

Hashemi³

et al. 2019

J Neurol Neurophysiol

View full text Add to dashboard Cite

show abstract

“…This beneficial effect is most probably due to the antiplatelet actions of clopidogrel, which might lead to smaller thrombus size or to faster thrombus degradation and therefore to smaller infarct size [31][32][33] . However, clopidogrel also appears to exert antiinflammatory and antioxidant actions and to improve endothelial function, which might confer a neuroprotective effect during acute stroke [34][35][36][37] .…”

Section: Discussionmentioning

confidence: 99%

Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity

Τζιόμαλος

Giampatzis²,

Bouziana³

et al. 2016

Cerebrovasc Dis

View full text Add to dashboard Cite

Background: Clopidogrel reduces the risk of non-cardioembolic ischemic stroke, but it is unclear whether it affects the severity and outcome of stroke. We aimed at evaluating the effect of prior treatment with clopidogrel on acute non-cardioembolic ischemic stroke severity and in-hospital outcome. Methods: We prospectively studied 608 consecutive patients (39.5% males, age 79.1 ± 6.6 years) who were admitted with acute ischemic stroke. The severity of stroke was assessed at admission with the National Institutes of Health Stroke Scale (NIHSS). Severe stroke was defined as NIHSS ≥21. The outcome was assessed using the dependency rates that prevailed at the time of discharge (i.e. modified Rankin scale between 2 and 5) and with in-hospital mortality. Results: At admission, 397 patients did not have atrial fibrillation or heart valve disease. Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment. The prevalence of severe stroke was lower in patients who were receiving clopidogrel than in patients who were receiving aspirin and patients who were not on antiplatelets (1.4, 13.0 and 11.0%, respectively; p < 0.05). Independent predictors of severe stroke at admission were male gender (relative risk (RR) 0.31, 95% CI 0.12-0.78, p < 0.05) and treatment with clopidogrel prior to stroke compared with no antiplatelet treatment (RR 0.13, 95% CI 0.02-0.97, p < 0.05). Treatment with aspirin prior to stroke did not predict severe stroke compared with no antiplatelet treatment (RR 1.24, 95% CI 0.51-2.98, p = NS). The rate of dependency at discharge did not differ between patients who were receiving clopidogrel, patients who were receiving aspirin and those who were not on antiplatelets (57.9, 47.8 and 59.7%, respectively; p = NS). Independent predictors of dependency at discharge were age (RR 1.12, 95% CI 1.05-1.19, p < 0.001) and NIHSS at admission (RR 1.67, 95% CI 1.46-1.92, p < 0.001). In-hospital mortality rate also did not differ between patients who were receiving clopidogrel, patients who were receiving aspirin and those who were not on antiplatelets (4.3, 4.3 and 5.0%, respectively; p = NS). The only independent predictor of in-hospital mortality was NIHSS at admission (RR 1.22, 95% CI 1.14-1.30, p < 0.001). Conclusions: Treatment with clopidogrel prior to acute non-cardioembolic ischemic stroke attenuates the severity of stroke at admission but does not appear to affect the functional outcome at discharge or the in-hospital mortality of these patients.

show abstract

Effects of memantine and clopidogrel alone and in combination in a cerebral ischemia-reperfusion model

Cited by 2 publications

References 25 publications

Effect of Memantine on Oxidative and Antioxidant Indexes Among Elderly Patients with Prediabetes and Mild Cognitive Impairment

Effect of Memantine on Oxidative and Antioxidant Indexes Among Elderly Patients with Prediabetes and Mild Cognitive Impairment

Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity

Contact Info

Product

Resources

About